France-based biotech company Valneva (EPA: VLA) is to take direct control over the marketing and distribution of Ixiaro, the travel vaccine against Japanese encephalitis.
This terminates the marketing and distribution agreement with UK pharma major GlaxoSmithKline (LSE: GSK) related to Ixiaro, signed in 2006 with Novartis' (NOVN: VX) vaccines division. It has been possible due to specific contract provisions following the asset swap between Novartis and GSK, and supports Valneva’s strategy to build an independent and fully-integrated vaccines biotech company and use the potential of Dukoral, the company’s recently-acquired second travel vaccine.
It expects to significantly improve sales margins and profitability from Ixiaro. Valneva believes that it will be able to continue to grow in-market sales from current levels by giving it full focus and attention, and by entering markets where the vaccine is approved but not marketed. After a transition period expected to last until early 2016 in all major territories, Valneva will market and distribute the Japanese encephalitis vaccine through a combination of its own sales and marketing teams, and country-specific marketing and distribution arrangements with established local partners.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze